- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03041844
Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The two most common types of chronic wounds are venous ulcers (VUs) and diabetic ulcers (DUs). The investigators will conduct the first double-blind randomized controlled trial (RCT) to test the effect of low-frequency, low-intensity (LFLI) ultrasound (US) on chronic wound healing and health related quality of life (HRQOL) with high statistical confidence (α < 0.05, power > 0.90, n=60 VUs, n=60 DUs). The investigators' approach combines this active therapy with non-invasive diagnostic monitoring of wound hemodynamics throughout the treatment cycle, and includes analysis of the impact of nutritional status and inflammation on wound closure. There are several innovative aspects of this work. Specifically, (1) The lightweight, battery-powered applicator is the first potentially wearable ultrasound wound therapy device that is safe to apply for extended periods of time. (2) The applicator actively promotes healing, which is fundamentally different from commercial ultrasonic systems that remove necrotic tissue only. (3) The study approach will link LFLI US exposure to changes in wound hemodynamics and HRQOL, which has the potential to enable personalized medicine. (4) The analysis of patient nutritional and systemic inflammatory status may enable further treatment customization by identifying those patients most likely to benefit from LFLI US therapy. (5) The study approach incorporates both disease-specific and generic measures of HRQOL, which is unique for a therapeutic ultrasound RCT.
The low-frequency, low-intensity (20 kiloHertz (kHz), <100 milliWatt per square centimeter (mW/cm2) spatial peak-temporal peak), portable ultrasound applicator is lightweight (<25g) and permits safe and clinically pragmatic wound treatment. The field parameters of the US device were previously optimized for venous ulcers, and three recent pilot clinical human studies (VUs: n=20, n=25; DUs: n=10) demonstrated that the treatment improved healing by 15% per week compared to sham treatment. The investigators therefore anticipate that our treatment will accelerate closure of chronic wounds, and hypothesize that (1) LFLI US will improve generic and disease-specific HRQOL scores, (2) LFLI US will activate beneficial changes in the microvasculature of the wound and surrounding tissue, and (3) individuals with poor nutrition and high levels of inflammation will have delayed wound healing.
The specific aims are to: (1) Assess the effect of LFLI US on VUs and DUs by measuring wound closure as a primary endpoint and generic and disease-specific HRQOL as secondary endpoints. (2) Monitor the effects of LFLI US on wound perfusion and oxygenation using non-invasive optical methods, and (3) Determine the impact of nutritional status and inflammation on closure of DUs and VUs. Overall, this work will validate LFLI US as a safe, portable, and cost-effective therapy for chronic wounds. This is important because new therapies and improved clinical paradigms for wound management are urgently needed. Over the long-term, the study findings may enable the development of personalized wound treatment regimens across care settings.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Temple University School of Podiatric Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a venous ulcer (VU) or diabetic ulcer (DU) that has been documented for at least 8 weeks without complete re-epithelialization and is larger than 0.75 cm2 in size.
- VUs must be present on the lower extremities non-weight-bearing areas.
- DUs must be present on the ankle or foot and be secondary to complications from diabetes.
- Patients with DUs must have a documented history of diabetes mellitus of at least six months.
Exclusion Criteria:
- VUs secondary to any connective tissue disorder or blood dyscrasias.
- Severe vascular insufficiency (ankle-brachial index lower than 0.75 or toe-brachial index below 0.5).
- Active, untreated infection
- Acute deep venous thrombosis
- Cutaneous malignancy present on the involved extremity
- Active (or past 6 months) cancer treatment
- Presence of both a diabetic ulcer and a venous ulcer on the same extremity
- Known allergy to Tegaderm (a polyurethane dressing)
- Pregnant women
- Individuals younger than 18 years of age regardless of emancipation status
- Prisoners
- Individuals unable to speak English, Spanish, or Mandarin
- Adults unable to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Low Frequency, Low Intensity Ultrasound
Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
|
Therapeutic ultrasound (20 kHz, <100 mW/cm2 spatial peak-temporal peak)
|
SHAM_COMPARATOR: Sham Ultrasound
Sham ultrasound applied weekly for up to 16 weeks.
|
Sham ultrasound applicator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in wound size
Time Frame: 4 weeks
|
Percentage change in wound size over 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound closure
Time Frame: 16 weeks
|
Complete wound closure at 16 weeks
|
16 weeks
|
Health Related Quality of Life (HRQOL)
Time Frame: 16 weeks, then 6 and 12 months after last treatment
|
Short form health survey will be administered to assess changes in HRQOL
|
16 weeks, then 6 and 12 months after last treatment
|
Wound Quality of Life (WQOL)
Time Frame: 16 weeks
|
Health survey will be administered to assess changes in wound-related HRQOL
|
16 weeks
|
Wound oxyhemoglobin concentration change
Time Frame: 16 weeks
|
Change in wound oxyhemoglobin concentration per week, measured with diffuse near infrared spectroscopy (DNIRS)
|
16 weeks
|
Microcirculatory blood flow index change
Time Frame: 16 weeks
|
Change in microcirculatory blood flow index per week, measured with diffuse correlation spectroscopy (DCS)
|
16 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter A Lewin, PhD, Drexel University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1609004864
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on Low Frequency, Low Intensity Ultrasound
-
Virginia Polytechnic Institute and State UniversityNot yet recruiting
-
Virginia Polytechnic Institute and State UniversitySalem VA Medical Center; Washington DC VA Medical CenterNot yet recruitingChronic Pain | Opioid Use Disorder | Anxiety DisorderUnited States
-
Virginia Polytechnic Institute and State UniversityEnrolling by invitation
-
Sheba Medical CenterCompletedTrigeminal Neuralgia | Tic DouloureuxIsrael
-
Duke UniversityAmerican Heart AssociationRecruiting
-
Chongqing Medical UniversityRecruitingThe Therapeutic Effect of Low-intensity Focused Ultrasound on Painful Diabetic Peripheral NeuropathyPainful Diabetic NeuropathyChina
-
Instituto Nacional de Ciencias Medicas y Nutricion...Actipulse NeuroscienceTerminatedMild Cognitive Impairment | Mild DementiaMexico
-
Carilion ClinicVirginia Polytechnic Institute and State UniversityRecruitingChronic Pain | Fibromyalgia | Complex Regional Pain SyndromesUnited States
-
Medical University of South CarolinaDart Therapeutics. LLCRecruitingMajor Depressive Disorder | Treatment Resistant DepressionUnited States
-
SonogenixCompleted